710703Disease Modification of Asthma by molecules derived from TB bacteriaClosedGRD Proof of ConceptInnovate UKTuberculosis bacteria (mTB) are present in about 2 billion people worldwide; they have evolved over millennia to remain hidden in the body by producing proteins that modulate the host's immune system. These proteins have been shown to interact with and reduce the body's natural inflammatory processes. Peptinnovate’s innovation Peptinnovate’s approach is to unlock the anti-inflammatory activity of these proteins and to develop new medicines for debilitating diseases such as asthma and COPD. Building on evolution, nature's ingenuity and employing Peptinnovate’s drug discovery and development skills we have modified these proteins to more drug-like molecules and are progressing the candidate molecule, PIN201104, to the clinic. Aims Following exciting preclinical data in the murine house dust mite (HDM) asthma model for the lead candidate PIN201104 Peptinnovate will progress the molecule into in vivo and in vitro mechanism of action studies to; unravel the mechanism of action of the peptide in asthma animal models and translate this mechanism into an in vitro setting in human cells. These studies will then lead to an in vitro biomarker assay for use in clinical studies in healthy volunteers and guide phenotypic positioning of PIN201104 in severe, steroid refractive asthma. Objectives • To perform in vivo studies in murine asthma models to determine if PIN201104 effects airway hyperreactivity (asthma) • To perform in vivo studies to ascertain the appropriate dosing regimen and route of delivery for PIN201104 for the treatment of asthma Benefits, outcomes and impacts The worldwide market for inflammatory disease treatment is substantial (>$70 billion), however recent safety scares have been attributed to a number of key drugs. Peptinnovate’s paradigm shift in potential treatment options will have a profound impact on the lives of millions of patients, reducing the burden on the healthcare providers and helping to build a sustainable UK biotech company